Kipra - grieķu - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

rotexmedica gmbh - ΘΕΙΟΠΕΝΤΆΛΗ ΤΟ ΝΆΤΡΙΟ ΚΑΙ ΤΟ ΑΝΘΡΑΚΙΚΌ ΝΆΤΡΙΟ - powder for injection - 1000mg/vial - 8000004465 - thiopental sodium and sodium carbonate - 1000 mg - thiopental

Kipra - grieķu - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

bendalis gmbh (0000011779) keltenring 17, oberhaching, 82041 - octreotide - solution for injection or infusion - 0.1mg/ml - octreotide (0083150769) 0,1mg

Kipra - grieķu - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

dr. falk pharma gmbh (0000008100) leinenweberstr. 5, freiburg, d-79108 - mesalazine - enema - 4g/60ml - mesalazine (0000089576) 4g - mesalazine

Kipra - grieķu - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

dr. falk pharma gmbh (0000008100) leinenweberstr. 5, freiburg, d-79108 - mesalazine - suppositories - 500mg - mesalazine (0000089576) 500mg - mesalazine

Eiropas Savienība - grieķu - EMA (European Medicines Agency)

sandoz gmbh - adalimumab - arthritis, rheumatoid; arthritis, psoriatic; spondylitis, ankylosing; uveitis; hidradenitis suppurativa; colitis, ulcerative; arthritis, juvenile rheumatoid; crohn disease; skin diseases, papulosquamous - Ανοσοκατασταλτικά - rheumatoid arthritishyrimoz in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. hyrimoz μπορεί να χορηγηθεί ως μονοθεραπεία σε περίπτωση μη ανοχής στη μεθοτρεξάτη ή όταν η συνεχιζόμενη θεραπεία με μεθοτρεξάτη είναι ακατάλληλη. Το adalimumab έχει αποδειχθεί ότι μειώνει το ρυθμό εξέλιξης της αρθρικής βλάβης, όπως αξιολογείται ακτινολογικά και ότι βελτιώνει τη λειτουργική ικανότητα όταν χορηγείται σε συνδυασμό με μεθοτρεξάτη. juvenile idiopathic arthritis- polyarticular juvenile idiopathic arthritishyrimoz in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). hyrimoz μπορεί να χορηγηθεί ως μονοθεραπεία σε περίπτωση μη ανοχής στη μεθοτρεξάτη ή όταν η συνεχιζόμενη θεραπεία με μεθοτρεξάτη είναι ακατάλληλη. Το adalimumab δεν έχει μελετηθεί σε ασθενείς ηλικίας κάτω των 2 ετών. - enthesitis-related arthritishyrimoz is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. axial spondyloarthritis- ankylosing spondylitis (as)hyrimoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. - axial spondyloarthritis without radiographic evidence of ashyrimoz is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and / or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs. psoriatic arthritishyrimoz is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. Το adalimumab έχει αποδειχθεί ότι μειώνει το ρυθμό εξέλιξης της περιφερικής αρθρικής βλάβης, όπως αξιολογείται ακτινολογικά σε ασθενείς με πολυαρθρική συμμετρική υποτύπων της νόσου και βελτιώνει την φυσική λειτουργία. psoriasishyrimoz is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasishyrimoz is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)hyrimoz is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy. crohn’s diseasehyrimoz is indicated for treatment of moderately to severely active crohn’s disease in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseasehyrimoz is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies.  paediatric ulcerative colitishyrimoz is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. ulcerative colitishyrimoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitishyrimoz is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitishyrimoz is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Eiropas Savienība - grieķu - EMA (European Medicines Agency)

mylan pharmaceuticals limited - υδροχλωρική μεμαντίνη - Νόσου Αλτσχάιμερ - other anti-dementia drugs, psychoanaleptics, - Θεραπεία ασθενών με μέτρια έως σοβαρή νόσο του alzheimer.

Kipra - grieķu - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

bpl bioproducts laboratory gmbh (0000011488) dornhofstrasse 34, neu-isenburg, 63263 - anti-d immunglobulin - solution for injection - 50mcg/ml - anti-d immunglobulin (8000031029) 500iu - anti-d (rh) immunoglobulin

Kipra - grieķu - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

ge healthcare buchler gmbh & co kg (0000003641) gieselweg 1, braunschweig, 38110 - sodium iodide (131 i) - capsule,hard - 37mbq to 5.55gbq - sodium iodide (131 i) (0007790263) 222gbq

Kipra - grieķu - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

bpl bioproducts laboratory gmbh (0000011488) dornhofstrasse 34, neu-isenburg, 63263 - albumin human - solution for infusion - 20% - albumin human (8000020282) 200g - albumin

Eiropas Savienība - grieķu - EMA (European Medicines Agency)

ultragenyx germany gmbh - vestronidase alfa - Βλεννοπολυσακχαρίδωση vii - Ένζυμα - mepsevii ενδείκνυται για τη θεραπεία του μη-νευρολογικές εκδηλώσεις της Βλεννοπολυσακχαρίδωσης vii (mps τύπου vi, sly σύνδρομο).